HSBC: Maintain "Buy" rating on HYSAN DEV (00014) with target price lowered to HK$14.38
According to DBS, the rental contribution from Shanghai Lujia, acquired by Keppel Land in 2021, continued to grow steadily, with the pre-lease commitment rate for office space increasing to around 80%.
DBS Research report released, maintaining a "buy" rating for HYSAN DEV (00014), with the target price lowered from HK$15 to HK$14.38, believing that the stock price has already reflected the negative factors.
The report mentioned that with the expansion of the portfolio and completion of renovation projects, HYSAN DEV's rental income is expected to improve. After the renovation of Lee Garden is fully completed, more than 10 flagship stores of renovated and expanded brands will be added to Henderson's luxury retail property portfolio, increasing the area by 40% compared to before.
Furthermore, DBS stated that the rental contribution from Lee Garden in Shanghai, acquired by Henderson in 2021, continues to grow, with the pre-commitment rate for office spaces increasing to about 80%. With the new rental contribution from Lee Garden Phase Eight expected to be completed in the second quarter of the 2026 fiscal year, even considering the ongoing negative rental returns from its Hong Kong office portfolio, Henderson's rental income is expected to increase in the coming years.
Related Articles

CHINFMINING(01258): Regarding the tailings dam incident, Qianbi Xi wet method has already fully fulfilled the repair and governance obligations in accordance with government instructions.

A-share hot topics in the evening | NVIDIA invests $5 billion in Intel

Energizer Medicine-B (02595): Hong Kong public offering oversubscribed by 2662.79 times, net proceeds from global offering approximately 1.67 billion Hong Kong dollars.
CHINFMINING(01258): Regarding the tailings dam incident, Qianbi Xi wet method has already fully fulfilled the repair and governance obligations in accordance with government instructions.

A-share hot topics in the evening | NVIDIA invests $5 billion in Intel

Energizer Medicine-B (02595): Hong Kong public offering oversubscribed by 2662.79 times, net proceeds from global offering approximately 1.67 billion Hong Kong dollars.

RECOMMEND

Three-Year R&D Spend Drains RMB 2.4 Billion, Urgent Cash Needs Drive Maiwei Biotech Back to Hong Kong Amid Compliance Scrutiny
18/09/2025

Why Generating Profit Remains Challenging for Lidar Companies
18/09/2025

SEC Adopts Landmark Rule to Restrict Shareholder Class Actions in Bid to Revive IPO Market
18/09/2025